ubmslateOT-logo-ubm

OT mobile menu

Search form

Topics:

Home

Combination Therapy Active in Children, AYAs With Hodgkin Lymphoma

Brentuximab vedotin combined with gemcitabine may be a new treatment option for children and AYA patients with Hodgkin lymphoma.

Image © tomorn pukesorn/Shutterstock.com

Recent Content

Researchers have identified two distinct stem cell–like populations from which relapse can arise in AML patients, which may help clinicians identify who will and won't respond to standard chemotherapy.

The 70-gene test could aid clinicians and patients in determining the optimal treatment course for breast cancer patients with a very low risk of death from the disease.

We spoke with Mrinal M. Gounder, MD, about next-generation sequencing for sarcoma, and how it can be used to inform treatment decisions and prognosis.

ODAC approval of Novartis' CAR T-Cell therapy paves the way for its FDA approval as a commercially available treatment for B-cell ALL.

RNA splicing variants were found to be critical drivers of prostate cancer aggressiveness and therapeutic resistance in African American men.

Using sticky nanoparticles, researchers have discovered a strategy to improve the immune system's detection of cancer proteins in order to optimize the effectiveness of immunotherapy.

Researchers have discovered a way to test for multiple neuroblastoma-associated genes simultaneously, which may help to improve definition of disease status in patients with relapsed/refractory neuroblastoma.

By clicking Accept, you agree to become a member of the UBM Medica Community.